pandem
creat
urgent
unpreced
need
rapid
largescal
diagnost
test
inform
time
patient
manag
studi
compar
two
recentlyauthor
rapid
test
cepheid
xpert
xpress
abbott
id
roch
coba
assay
total
nasopharyng
swab
test
includ
posit
span
full
rang
observ
c
valu
coba
assay
compar
coba
overal
posit
agreement
id
xpert
neg
agreement
id
xpert
respect
id
xpert
show
posit
agreement
medium
high
viral
concentr
c
valu
howev
c
valu
posit
agreement
id
xpert
find
highlight
import
limit
id
specimen
collect
viral
univers
transport
media
low
viral
concentr
studi
need
evalu
perform
id
direct
swab
sever
acut
respiratori
viru
coronaviru
emerg
wuhan
china
decemb
sinc
rapidli
spread
across
world
caus
global
pandem
coronaviru
diseas
major
case
mild
moder
sever
infect
overwhelm
healthcar
system
unit
state
particularli
new
york
citi
realtim
polymeras
chain
reaction
rtpcr
viral
rna
nasal
nasopharyng
swab
becom
standard
method
use
confirm
diagnosi
first
quantit
rtpcr
test
detect
design
distribut
januari
world
health
organ
unit
state
mani
countri
howev
slow
rollout
largescal
diagnost
test
long
turnaround
time
associ
laboratori
test
particularli
sent
refer
laboratori
significantli
hamper
public
health
effort
contain
outbreak
contrast
commerciallyavail
rapid
diagnost
assay
better
inform
time
patient
manag
decis
guid
need
quarantin
isol
contact
trace
therapeut
manag
begin
march
multipl
rapid
test
receiv
emerg
use
author
eua
us
food
drug
administr
fda
howev
manufactur
submiss
eua
requir
evalu
limit
detect
crossreact
assay
address
import
perform
characterist
accuraci
precis
reproduc
addit
manufactur
submiss
includ
studi
contriv
posit
sampl
spike
viral
rna
assess
perform
clinic
patient
specimen
two
recentlyauthor
rapid
test
xpert
xpress
cepheid
sunnyval
ca
id
abbott
chicago
ccbync
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
il
manufactur
widescal
distribut
numer
medic
center
around
countri
limit
studi
two
assay
recent
publish
number
patient
sampl
evalu
date
rel
small
signific
question
remain
accuraci
test
across
full
spectrum
viral
load
coba
assay
util
rtpcr
amplifi
detect
two
viral
target
ab
nonstructur
region
uniqu
conserv
region
egen
structur
protein
envelop
pansarbecoviru
detect
xpert
assay
autom
rtpcr
amplifi
detect
two
viral
target
nucleocapsid
recombin
protein
uniqu
region
structur
envelop
egen
id
assay
use
proprietari
isotherm
nucleic
acid
amplif
technolog
qualit
detect
rdrp
gene
use
fluoresc
report
probe
patient
specimen
adult
rang
age
year
two
pediatr
patient
age
day
day
old
averag
age
year
ccbync
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
posit
sampl
year
neg
sampl
overal
major
posit
sampl
male
neg
sampl
femal
tabl
test
result
abbott
id
cepheid
xpert
shown
tabl
detect
egen
target
target
also
two
sampl
test
neg
coba
posit
xpert
sampl
c
valu
target
without
detect
egen
target
egen
target
c
valu
gener
cycl
lower
xpert
coba
supplement
materi
tabl
figur
publish
date
rel
perform
characterist
assay
especi
patient
specimen
repres
wide
rang
viral
concentr
ccbync
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
compar
analysi
xpert
assay
show
high
level
agreement
coba
assay
across
entir
rang
test
c
valu
includ
lowlevel
posit
find
confirm
publish
moran
et
al
show
high
level
agreement
two
assay
use
expand
number
posit
clinic
sampl
contrast
id
assay
reliabl
detect
specimen
c
valu
detect
major
swab
elut
transport
media
import
note
eua
id
recent
updat
remov
indic
swab
transport
media
data
support
eua
appropri
modifi
sampl
may
becom
dilut
vtm
lowlevel
posit
may
fals
test
neg
contrast
batch
test
higher
complex
requir
coba
assay
xpert
id
offer
shorter
turnaround
time
avail
nearpati
set
howev
two
assay
differ
throughput
capac
run
time
id
platform
run
singl
specimen
time
result
avail
minut
less
xpert
run
larger
randomaccess
platform
allow
significantli
higher
throughput
result
avail
minut
assay
avail
use
poc
set
introduc
benefit
drawback
one
hand
poc
molecular
test
deliv
shortest
possibl
interv
sampl
collect
result
facilit
faster
clinic
decisionmak
howev
concern
relat
assay
perform
qualiti
manag
safeti
poc
set
still
remain
studi
poc
molecular
test
influenza
respiratori
syncyti
viru
shown
promis
result
also
highlight
ccbync
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
concern
risk
contamin
fals
posit
also
much
higher
test
perform
outsid
control
environ
nonlaboratori
train
personnel
nevertheless
uniqu
circumst
rapidlyspread
pandem
may
ultim
necessit
widescal
adopt
poc
assay
complet
new
patient
set
walk
drivethru
test
center
limit
studi
includ
rel
number
sampl
pediatr
patient
two
sampl
patient
age
day
day
includ
neg
three
test
method
also
abl
evalu
id
specimen
transport
media
perform
assay
direct
nasal
swab
requir
evalu
subsequ
studi
anoth
limit
use
coba
assay
compar
assay
two
sampl
identifi
posit
xpert
basi
nucleocapsid
gene
detect
neg
target
coba
whether
sampl
truli
posit
truli
neg
could
determin
fast
readili
avail
reliabl
test
result
critic
import
pandem
three
assay
evalu
studi
hold
promis
deliv
valuabl
clinic
inform
headtohead
comparison
molecular
test
import
order
establish
use
method
help
medic
provid
determin
appropri
diagnost
test
best
serv
commun
copyright
holder
preprint
version
post
april
http
ccbync
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
sampl
coba
xpert
id
ccbync
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
ccbync
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
